Incyte Corporation
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Incyte Corporation sits in the top decile of US sponsors by registered trial count (#137 of 15,742 sponsors by registered trial count).
Incyte Corporation: 239 sponsored US clinical trials, 37 recruiting.
Incyte Corporation sponsors 239 registered US clinical trials on ClinicalTrials.gov, 37 of them currently recruiting, and 126 completed. 50 of these trials are in Phase 3-4 (later-stage) and 183 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Solid Tumors, with 7 trials.
Top-decile sponsor footprint
Incyte Corporation ranks in the top decile of sponsors by registered trial count (#137 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
126 of 186 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (67.7%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
239 total, page 5 of 5
Study of Ruxolitinib in Colorectal Cancer Patients
NCT02119676
Study of Ruxolitinib in Pancreatic Cancer Patients (Janus 1)
NCT02117479
Ruxolitinib in Combination With Pemetrexed/Cisplatin in Non Small Cell Lung Cancer
NCT02119650
Randomized Open-Label Study of INCB047986 in Subjects With Primary Myelodysplastic Syndrome (MDS)
NCT02093429
An Open-Label Study of a Novel JAK-inhibitor, INCB047986, Given in Patients With Advanced Malignancies
NCT01929941
Safety Study of Itacitinib (INCB039110) in Combination With Gemcitabine and Nab-Paclitaxel in Subjects With Advanced Solid Tumors
NCT01858883
An Open-Label Study of Ruxolitinib Given With Chemotherapy in Patients With Advanced Solid Tumors
NCT01822756
A Phase 2 Study of the IDO Inhibitor Epacadostat Versus Tamoxifen for Subjects With Biochemical-recurrent-only EOC, PPC or FTC Following Complete Remission With First-line Chemotherapy
NCT01685255
An Open Label Study of Itacitinib Administered Orally in Patients With Myelofibrosis
NCT01633372
Randomized Switch Study From Hydroxyurea to Ruxolitinib for RELIEF of Polycythemia Vera Symptoms: The Relief Study
NCT01632904
A Study of Escalating Doses of Itacitinib Administered Orally in Patients With Plaque Psoriasis
NCT01634087
A Phase 1/2 Randomized, Blinded, Placebo Controlled Study of Ipilimumab in Combination With Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma
NCT01604889
A Study Exploring the Safety, Tolerability, and Efficacy of a 28 Day Course Followed by an Additional 56 Day Course of Itacitinib in Subjects With Active Rheumatoid Arthritis
NCT01626573
Alternative Dosing Strategy of Ruxolitinib in Patients With Myelofibrosis
NCT01445769
Study of Ruxolitinib in Pancreatic Cancer Patients
NCT01423604
Ruxolitinib (INCB018424) in Participants With Primary Myelofibrosis (PMF), Post Essential Thrombocythemia-myelofibrosis and Post Polycythemia Vera-myelofibrosis (PPV-MF)
NCT01348490
Study of the JAK Inhibitor Ruxolitinib Administered Orally to Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera-Myelofibrosis (PPV-MF) or Post-Essential Thrombocythemia-Myelofibrosis (PET-MF)
NCT01317875
Study of Ruxolitinib (INCB018424) Sustained Release Formulation in Myelofibrosis Patients
NCT01340651
Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: (The RESPONSE Trial)
NCT01243944
Safety and Efficacy of INCB007839 With Trastuzumab and Vinorelbine in Patients With Metastatic HER2+ Breast Cancer
NCT01254136
A Dose-escalation Study in Subjects With Advanced Malignancies
NCT01195311
A Dose-escalation Study in Subjects With Advanced Malignancies
NCT01072266
COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I Trial
NCT00952289
INCB028050 Compared to Background Therapy in Patients With Active Rheumatoid Arthritis (RA) With Inadequate Response to Disease Modifying Anti-Rheumatic Drugs
NCT00902486
A Dose Ranging Study of the Effect of Ruxolitinib Phosphate Cream When Applied to Participants With Plaque Psoriasis
NCT00778700
Study to Determine the Safety and Efficacy of INCB018424 in Patients With Polycythemia Vera or Essential Thrombocythemia
NCT00726232
Safety and Efficacy of INCB013739 Plus Metformin Compared to Metformin Alone on Glycemic Control in Type 2 Diabetics
NCT00698230
Evaluate the Safety and Tolerability of INCB019602 When Administered With Metformin in Patients With Type 2 Diabetes
NCT00698789
A Study to Determine the Effect and Safety of an Oral Janus Kinase 2 (JAK2)-Inhibitor (Ruxolitinib; INBC018424) in Patients With Multiple Myeloma
NCT00639002
Study of Ruxolitinib (INCB018424) Administered Orally to Patients With Androgen Independent Metastatic Prostate Cancer
NCT00638378
A Study Exploring the Safety, Tolerability and Efficacy of a 4 Week Course of INCB018424 in Subjects With Active Rheumatoid Arthritis
NCT00550043
Open Label, Safety and Efficacy Study of Topical Investigational Drug to Treat Patients With Psoriasis
NCT00617994
Open Label Ruxolitinib (INCB018424) in Patients With Myelofibrosis and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis
NCT00509899
A Study of Ruxolitinib Phosphate Cream When Applied to Patients With Plaque Psoriasis
NCT00820950
Pharmacodynamic Study of the Effect of INCB013739 on Insulin Sensitivity in Obese, Type 2 Diabetic Subjects
NCT00478322
A Study of the Effect of INCB013739 on Cortisone Reducing Enzyme Activity in Obese People Predisposed to Diabetes
NCT00398619
Safety/Effectiveness of Oral Chemokine Coreceptor 5 (CCR5) Antagonist INCB009471 in R5-tropic HIV Infected Patients
NCT00393120
Randomized, Double-Blind Study Comparing Dexelvucitabine (DFC) to Lamivudine (3TC) in Subjects With Resistance to NRTIs, PIs, and NNRTIs
NCT00300573
Open-Label Study to Assess the Safety/Tolerability in Patients With Solid Tumors
NCT00820560
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 100 |
| Phase 2 | 83 |
| Phase 3 | 49 |
| Phase 4 | 1 |
What is open in the Incyte Corporation pipeline
37 recruiting of 239 indexed (15% open); 126 completed (53%).
Phase mix: 50 late (III/IV) vs 183 early (I/II) (early-phase heavy).
Top condition: Solid Tumors (7 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Incyte Corporation: open-pipeline peers nationwide
Peers matched on 239 registered trials and 15% open enrollment, not the therapeutic-area sidebar.
Incyte Corporation sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 239 trials (± recruiting share)
- University of Massachusetts, Worcester · 240 trials · 13% recruiting
- Loma Linda University · 237 trials · 15% recruiting
- Daiichi Sankyo · 236 trials · 12% recruiting
- State University of New York at Buffalo · 243 trials · 21% recruiting
Sponsors near 15% open enrollment (± trial volume)
- Brigham and Women's Hospital · 15% recruiting · 937 trials
- Northwestern University · 15% recruiting · 1,209 trials
- Nationwide Children's Hospital · 15% recruiting · 188 trials
- University of Michigan Rogel Cancer Center · 15% recruiting · 292 trials
Related
What to do with this Incyte Corporation page
239 registered trials is a research-attention snapshot, not an endorsement of Incyte Corporation or any single study.
- 37 of Incyte Corporation's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Solid Tumors is the condition Incyte Corporation studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Solid Tumors trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Incyte Corporation pipeline card: 239 registered trials from official public datasets.Report a data error.